Dr. Kymora Bernisha Scotland, MD

Dr. Scotland practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Scotland's NPI, 1093005787, was assigned on April 14, 2011. Dr. Scotland graduated from Weill Cornell Medicine in 2011. Dr. Scotland holds California license A163209.

Dr. Scotland's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Scotland's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Scotland is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Scotland to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Scotland practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Scotland's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Scotland is board certified in urology by the American Board of Urology. Dmand AI has Dr. Scotland's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists enlarged prostate, kidney stone disease, urinary endoscopy, urine flow blockage and UTI among the conditions Dr. Scotland treats.

CMS data shows 457 Medicare services from Dr. Scotland across 8 procedure codes in 2024, for 140 Medicare patients. Medicare paid $40,712 for them.

CMS counts 140 Medicare patients who saw Dr. Scotland in 2024. The largest group is 65 to 74, with 78 patients. 74% of them have high cholesterol, and 73% have high blood pressure. 29% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Scotland's median patient age at 63, with 48% women.

In 2024, Dr. Scotland wrote 157 Medicare Part D claims for 48 patients. 92% of them were for generic drugs. CMS names the drug for 82 of them, across 2 drugs with 11 or more claims each, at $1,381 in total drug cost. In 2023, CMS named 103 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Scotland for performance year 2024, reported as part of a group. Dr. Scotland accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Scotland as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 20 papers to Dr. Scotland, published from 2017 to 2023. 2020 was the busiest year, with 6. The most frequent topics are Kidney Calculi and Nephrolithotomy, Percutaneous. Dr. Scotland's most frequent co-authors are Brian Howard Eisner, MD, Seth K. Bechis, MD and Kelly A. Healy, MD.

Dmand AI links Dr. Scotland to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Urologic Diseases and Female Urogenital Diseases.

CMS Open Payments shows 98 general payments to Dr. Scotland from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 37% of the total. Cook Medical LLC paid the most, $3,404.

Dr. Scotland graduated from Weill Cornell Medicine in 2011.

Dr. Scotland is in network with 13 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.